AOD-9604 research guide for Aus. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 won't be found on pharmacy shelves in Aus or most other cities — this is a specialist compound supplied via a dedicated online market. What this means for Aus researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those quality checks are within reach of all serious researchers. A properly operating AOD-9604 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. What follows is a vendor evaluation and quality guide built specifically around AOD-9604, covering everything a Aus researcher needs to source confidently.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Aus comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate AOD-9604 Vendors
Before looking at individual vendors, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. The combination of community consensus and independent COA review is the most reliable sourcing approach — community feedback surfaces systemic problems invisible in one transaction, and vice versa. For Aus researchers making a first AOD-9604 purchase: verify the vendor against this framework, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Aus
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Proper handling of AOD-9604 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed and related preprint servers represent the most comprehensive research databases for AOD-9604 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
